EPA Use of Psychedelic Treatments in Psychiatric Clinical Practice Guideline Summary - Guideline Central

Design and created by Guideline Central in participation with the European Psychiatric Association.

Document Overview

Document Title: Use of Psychedelic Treatments in Psychiatric Clinical Practice

Authoring Society: European Psychiatric Association

Document Publication Date: Oct 28, 2024

Page Last Reviewed/Updated: May 6, 2026

Document Type: Consensus Statement

Country of Publication: European

Full Text Freely Available: Yes

Full Text Guideline: www.cambridge.org/core/services/aop-cambridge-core/content/view/340B7D729CF69904BB989B24FA0D60F7/S0924933824018066a.pdf/use-of-psychedelic-treatments-in-psychiatric-clinical-practice-an-epa-policy-paper.pdf

Source Citation: Destoop M, Mohr P, Butlen F, Kéri P, Samochowiec J, De Picker L, Fiorillo A, Kuypers KPC, Dom G. Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper. Eur Psychiatry. 2025 Jan 10;68(1):e3. doi: 10.1192/j.eurpsy.2024.1806. PMID: 39791347; PMCID: PMC11795445.

Document Scope, Criteria, and Use Cases

Document Objectives: In this EPA policy paper, we highlight the potential benefits, and also the challenges of psychedelic treatments, which can be relevant for the future real-world implementation of these treatments.

Scope: Management, Treatment

Diseases/Conditions (MeSH)

D001523 - Mental Disorders

D011562 - Psilocybin

D001523 - Mental Disorders

D011562 - Psilocybin

Keywords: DMT, Psychedelics, Psychiatric disorders, psilocybin

Target Patient Population: Patients with various forms of mental disorders

Target Provider Population: Psychiatrists

Inclusion Criteria: Male, Female, Adult, Older Adult

Health Care Settings: Ambulatory

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant, Psychologist